Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: Prospects for regorafenib therapy

Hepatology Research : the Official Journal of the Japan Society of Hepatology
Takeshi TerashimaShuichi Kaneko

Abstract

This study aimed to investigate liver functional reserves during sorafenib treatment for advanced hepatocellular carcinoma (HCC), to identify predictive factors for maintaining them, and to analyze the proportion of candidates for regorafenib, which has been proven to improve patients' outcomes in the RESORCE trial. We retrospectively investigated Child-Pugh scores during and after sorafenib treatment and evaluated their effects on second-line treatment and outcomes of 125 patients with advanced HCC. Pretreatment Child-Pugh A was maintained in 59/90 (65.6%) patients and pretreatment Child-Pugh B was improved to Child-Pugh A in 10/35 (28.6%) patients when sorafenib ceased. A Child-Pugh score = 5 and aspartate amino transferase <40 IU/L before treatment were contributing factors; vascular invasion and cessation of sorafenib due to gastrointestinal or liver-related adverse effects were reverse predictive factors for Child-Pugh A when sorafenib treatment ceased. Significantly more patients with Child-Pugh A when sorafenib treatment ceased received subsequent therapy and achieved better outcomes compared with patients with Child-Pugh B. When sorafenib treatment failed, 45/125 patients (36.0%) fulfilled key inclusion criteria of the ...Continue Reading

References

Oct 27, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jordi BruixUNKNOWN Practice Guidelines Committee, American Association for the Study of Liver Diseases
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Oct 9, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T PressianiA Santoro
Apr 24, 2013·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Haruhiko TakedaYukio Osaki
Feb 18, 2014·Gut·Jordi BruixVincenzo Mazzaferro
Jan 9, 2016·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Feb 1, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T PressianiA Santoro

❮ Previous
Next ❯

Citations

Aug 26, 2018·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Atsushi HiraokaUNKNOWN Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clini
Apr 30, 2019·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Teiji KuzuyaMitsuhiro Fujishiro
Jun 23, 2020·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Takeshi Terashima
Apr 21, 2020·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Takeshi TerashimaShuichi Kaneko
Aug 13, 2020·Signal Transduction and Targeted Therapy·Ao HuangJian Zhou
Dec 24, 2018·Cancer Medicine·Atsushi HiraokaUNKNOWN Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in J
Nov 17, 2020·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Takeshi TerashimaShuichi Kaneko
Dec 9, 2020·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Chao-Chuan WuChing-Sheng Hsu
Jun 4, 2021·Journal of Hepatocellular Carcinoma·Alessandro GranitoFrancesco Tovoli
Jun 12, 2021·Cancer Reports·Atsushi HiraokaUNKNOWN Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics
Aug 30, 2019·Oncology·Atsushi HiraokaUNKNOWN On behalf of the Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts 
Jul 16, 2019·Oncology·Atsushi HiraokaUNKNOWN HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.